MARKET

NVTA

NVTA

Invitae Corp
NYSE

Real-time Quotes | Nasdaq Last Sale

2.970
+0.430
+16.93%
Closed 19:50 07/05 EDT
OPEN
2.480
PREV CLOSE
2.540
HIGH
2.980
LOW
2.410
VOLUME
11.61M
TURNOVER
--
52 WEEK HIGH
34.11
52 WEEK LOW
2.080
MARKET CAP
680.99M
P/E (TTM)
-1.4129
1D
5D
1M
3M
1Y
5Y
Pacific Biosciences of California, Invitae Modify Development and Commercial Agreement
MT Newswires · 5d ago
40 Stocks Moving In Wednesday's Mid-Day Session
 Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
Benzinga · 06/22 16:17
Signify (SGFY) Stock Jumps 6%: Will It Continue to Soar?
Signify (SGFY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 06/20 09:15
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 48.5% to $2.57 in pre-market trading after the company reached an agreement with Phillip Morris for international electronic nicotine delivery system product distribution.
Benzinga · 06/14 09:54
Stocks That Hit 52-Week Lows On Monday
  During Monday's trading, 1214 companies set new 52-week lows.
Benzinga · 06/13 16:18
Benchmark Adjusts Invitae's Price Target to $6 From $13, Reiterates Buy Rating
MT Newswires · 06/13 09:48
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Benzinga · 06/06 09:31
ADAP, SLDP and ZSAN among mid-day movers
Gainers: Turning Point Therapeutics (TPTX) +117%. Energy Focus (EFOI) +40%. Galecto (GLTO) +25%. Adaptimmune (ADAP) +22%. Amylyx Pharmaceuticals (AMLX) +22%. AudioEye (AEYE) +20%. Sprague Resources LP (SRLP) +20%. Global Cord
Seekingalpha · 06/03 16:42
More
No Data
Learn about the latest financial forecast of NVTA. Analyze the recent business situations of Invitae Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
30.00%Buy
40.00%Hold
10.00%Under-perform
0.00%Sell
Analyst Price Target
The average NVTA stock price target is 13.59 with a high estimate of 31.75 and a low estimate of 2.500.
High31.75
Average13.59
Low2.500
Current 2.970
EPS
Actual
Estimate
-0.73-0.55-0.36-0.18
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 396
Institutional Holdings: 210.17M
% Owned: 91.66%
Shares Outstanding: 229.29M
TypeInstitutionsShares
Increased
105
16.58M
New
47
4.65M
Decreased
84
22.27M
Sold Out
57
6.36M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.07%
Pharmaceuticals & Medical Research
+0.40%
Key Executives
Non-Executive Chairman/Independent Director
Eric Aguiar
President/Chief Executive Officer/Co-Founder/Director
Sean George
Chief Financial Officer
Yafei Wen
Chief Operating Officer
Kenneth Knight
Chief Accounting Officer
Robert Werner
Chief Compliance Officer/General Counsel/Secretary
Thomas Brida
Other
Robert Nussbaum
Other
Katherine Stueland
Other
Karthik Suri
Independent Director
Geoffrey Crouse
Independent Director
Christine Gorjanc
Independent Director
Kimber Lockhart
Independent Director
Chitra Nayak
No Data
No Data
About NVTA
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. These tests are delivered through a platform that serves patients, healthcare providers, biopharma companies and other partners, thereby capturing the potential of genetics and helping to expand its use across the healthcare continuum. It offers Invitae Digital Health, a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. The Company offers genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, personalized oncology, metabolic conditions, and rare diseases.

Webull offers kinds of Invitae Corp stock information, including NYSE:NVTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVTA stock methods without spending real money on the virtual paper trading platform.